◆ NeutralCRSPMSFTRXRX

3 Stocks With the Most Upside by the End of 2026

The Motley Fool·
3 Stocks With the Most Upside by the End of 2026

The article identifies three stocks with significant upside potential by end of 2026: CRISPR Therapeutics, expected to generate $40M in revenue this year and $160M+ next year as its Casgevy treatment gains traction; Microsoft, trading 40% below analyst price targets as management addresses cloud/AI business challenges; and Recursion Pharmaceuticals, an AI-driven drug discovery platform trading over 100% below analyst consensus with multiple developmental milestones approaching.

Read Full Article at The Motley Fool
← Back to Financial Intelligence